Concepedia

Els Vercammen

EV

14

Publications

2.1K

Citations

12

H-Index

1989

Active since

Affiliations

Johnson & Johnson (United States)(Current)

Janssen (Belgium)

Johnson & Johnson (United Kingdom)

Els Vercammen is an author at Johnson & Johnson (United States) specializing in medicine, pharmacotherapy, and coronary heart disease.

Top concepts

Publications per year

1989–2016

14

Publications

14

Effects of Epoetin Alfa on Hematologic Parameters and Quality of Life in Cancer Patients Receiving Nonplatinum Chemotherapy: Results of a Randomized, Double-Blind, Placebo-Controlled Trial

Timothy J. Littlewood, Emilio Bajetta, J.W.R. Nortier et al. · Journal of Clinical Oncology · 2001 · 976 citations

Maintaining Normal Hemoglobin Levels With Epoetin Alfa in Mainly Nonanemic Patients With Metastatic Breast Cancer Receiving First-Line Chemotherapy: A Survival Study

Brian Leyland‐Jones, Marek Pawlicki, Tadeusz Pieńkowski et al. · Journal of Clinical Oncology · 2005 · 663 citations · Full text

R 68 070: Thromboxane A2 Synthetase Inhibition and Thromboxane A2/Prostaglandin Endoperoxide Receptor Blockade Combined in One Molecule - II. Pharmacological Effects In Vivo and Ex Vivo

Fred De Clerck, Johan Beetens, A. Van de Water et al. · Thrombosis and Haemostasis · 1989 · 88 citations

Incidence of erythropoietin antibody-mediated pure red cell aplasia: the Prospective Immunogenicity Surveillance Registry (PRIMS)

Iain C. Macdougall, Nicole Casadevall, Francesco Locatelli et al. · Nephrology Dialysis Transplantation · 2014 · 76 citations · Full text

A Randomized, Open-Label, Multicenter, Phase III Study of Epoetin Alfa Versus Best Standard of Care in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy

Brian Leyland‐Jones, Igor Bondarenko, Gia Nemsadze et al. · Journal of Clinical Oncology · 2016 · 66 citations

Rows per page

1–5 of 14